Advanced search
Publication Cover
Infectious Diseases Volume 51, 2019 - Issue 4
Submit an article Journal homepage
160
Views
6
CrossRef citations to date
0
Altmetric
Letter to the Editor

Risk factors for pneumocystis pneumonia onset in HIV-negative patients treated with high-dose systemic corticosteroids

Takemasa MatsumotoDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
,
Masaki FujitaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JapanCorrespondence[email protected]
,
Ryousuke HiranoDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
,
Tomoya SasakiDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
&
Kentaro WatanabeDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
Pages 305-307 | Received 11 Nov 2018, Accepted 06 Dec 2018, Published online: 18 Feb 2019

References

  • Fritzsche C, Ghanem H, Koball S, et al. High Pneumocystis jirovecii colonization rate among hemodialysis patients. Infect Dis (Lond). 2017;49:132–136.
  • Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77:644–649.
  • Wada T, Sho N, Ogawa E, et al. Risks and benefits of trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis in connective tissue disease (CTD) patients receiving high-dose corticosteroid therapy. Kitasato Med J. 2014;44:97–110.
  • Gonzalez Santiago TM, Wetter DA, Kalaaji AN, et al. Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol. 2016;55:823–830.
  • Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874–1876.
  • Yukawa K, Nagamoto Y, Watanabe H, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim/sulfamethoxazole. J Clin Rheumatol. 2018;24:355–360.
  • Aoki Y, Iwamoto M, Kamata Y, et al. Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009;29:1327–1330.
  • Chen M, Tian X, Qin F, et al. Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death. PLoS One. 2015;10:e0139144.
  • Asai N, Motojima S, Ohkuni Y, et al. Clinical manifestations and prognostic factors of Pneumocystis jirovecii pneumonia without HIV. Chemotherapy. 2017;62:343–349.
  • Iikuni N, Kitahama M, Ohta S, et al. Evaluation of pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006;16:282–288.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.